Jaya Sangodkar, Ph.D.
Affiliations: | 2012 | Cancer Biology | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Area:
Molecular Biology, Cell Biology, Genetics, OncologyGoogle:
"Jaya Sangodkar"Parents
Sign in to add mentorGoutham Narla | grad student | 2012 | Mount Sinai School of Medicine | |
(The Role of KLF6 Gene in Lung Cancer.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Rasool RU, O'Connor CM, Das CK, et al. (2023) Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. Nature Communications. 14: 5253 |
O'Connor CM, Taylor SE, Miller KM, et al. (2021) Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma. Cancer Research |
Scarpa M, Singh P, Bailey CM, et al. (2021) PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-Myc and Pim-1 proteasomal degradation. Molecular Cancer Therapeutics |
Noto FK, Sangodkar J, Adedeji BT, et al. (2020) The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. Plos One. 15: e0240169 |
Coles GL, Cristea S, Webber JT, et al. (2020) Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell |
Farrington CC, Yuan E, Mazhar S, et al. (2019) Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. The Journal of Biological Chemistry |
O'Connor CM, Leonard D, Wiredja D, et al. (2019) Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene |
Taylor SE, O'Connor CM, Wang Z, et al. (2019) The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Research |
Tohmé R, Izadmehr S, Gandhe S, et al. (2019) Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. Jci Insight. 4 |
Mazhar S, Taylor SE, Sangodkar J, et al. (2019) Targeting PP2A in cancer: Combination therapies. Biochimica Et Biophysica Acta. Molecular Cell Research. 1866: 51-63 |